1. Home
  2. |Insights
  3. |FAR Council Finalizes Definition of Prohibited "Recruitment Fees" Under Anti-Trafficking Regulations

FAR Council Finalizes Definition of Prohibited "Recruitment Fees" Under Anti-Trafficking Regulations

Client Alert | 1 min read | 12.26.18

On December 20, 2018, the DoD, GSA, and NASA issued a final rule to define “recruitment fees” under FAR subpart 22.17, Combating Trafficking in Persons, and the associated contract clause at FAR 52.222–50. While the prohibition against charging employees “recruitment fees” was added to the regulations in 2015, the FAR Council did not include a definition at that time.

The FAR Council has now finalized the expansive definition, which includes various types of fees that contractors, subcontractors, and their employees or agents are prohibited from charging to employees or potential employees that are covered by FAR 52.222–50. Specifically, “recruitment fees” are fees of any type, including charges, costs, assessments, or other financial obligations, that are associated with the recruiting process, regardless of the time, manner, or location of imposition or collection of the fee. The definition also includes thirteen representative examples, including but not limited to, fees for: (i) obtaining permanent or temporary labor certifications; (ii) acquiring visas; (iii) acquiring photographs and identity or immigration documents, such as passports; (iv) government-mandated fees, such as border crossing fees, levies, or worker welfare funds; and (v) certain transportation and subsistence costs. Such fees are considered “recruitment fees” regardless of whether they are paid in property, money or deducted from wages; and even if the fee is paid back to the employee, or collected by a third party.

Insights

Client Alert | 4 min read | 04.18.24

Maryland and Colorado Say the Price Isn’t Right: State Drug Affordability Review Boards Seek Drug Upper Payment Limits

Following federal lawmakers’ initiative to lower prescription drug prices under the Inflation Reduction Act of 2022, several states have taken similar steps to limit certain drugs’ prices. Drug affordability for consumers is a top priority for federal and state lawmakers and regulators because it is a bipartisan issue that directly impacts consumers’ wallets. With negotiations between the federal government and drug manufacturers over 10 drugs’ prices for Medicare beneficiaries well underway under the Inflation Reduction Act, 11 states, including Maryland and Colorado, have created drug affordability review boards to more directly tackle rising prices for both brand and generic drugs.[1] And another 12 states have pending legislation to create these boards.[2] ...